LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on congenital heart disease. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat congenital heart disease.
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market during the forecast period.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
Congenital heart disease - market overview
Congenital heart disease is a structural defect in the heart valve, heart wall, or arteries and veins. This disease leads to disruption of the blood flow, which can later lead to life-threatening conditions such as heart failure. Some of the symptoms include excessive sweating, tiredness and fatigue, fast breathing, clubbed fingernails, and a blue tinge to the skin.
According to a senior analyst at Technavio for cardiovascular and metabolic disorders, “Congenital heart disease is also known as congenital heart anomaly or a congenital heart defect. It can be defined as a type of disease, which is related to the abnormal structure of the heart.”
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Congenital heart disease segmentation
This market research report segments the congenital heart disease market based on therapies employed that includes monotherapy and unknown, RoA (oral, IV, intracoronary, and unknown), therapeutic modalities (small molecules, biological, and gene therapy), targets for drugs under development (endothelin receptor, ultrasonography enhancer, PDPE-5, ACE, and unknown), MoA (cell replacement, ACE inhibitor, endothelin receptor inhibitor, ultrasonography enhancer inhibitor, and PDPE-5 inhibitor), drugs under development (discovery, phase I, phase II/III, and phase III), and recruitment status (ongoing, recruiting, and unknown). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
|
Save big with Technavio this May! Find out what companies are venturing in to beat the heat this summer! Technavio indulges you with a massive 20% OFF on all non-alcoholic beverages reports for the entire month. OR Technavio honors the achievements and efforts of Motherhood this Mother's Day by offering a whopping 30% OFF on all cosmetics and toiletry reports. Offer valid from 7th May for a limited period. |
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
